Takeda’ s Adcetris Wins “Landmark” Cancer Drugs Fund First In UK
Takeda’s Adcetris has received expanded recommendations from England’s health technology appraisal institute, NICE, following data collected through the Cancer Drugs Fund.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.